FBLG
FibroBiologics, Inc.
Key Financials
Net Income
$-18646000
↓ 67.1%
Total Liabilities
$3.5M
↓ 74.7%
Operating Income
$-16649000
↓ 21.2%
Cash & Equivalents
$4.9M
↓ 65.0%
EPS (Diluted)
$-0.42
↓ 23.5%
Total Assets
$9.6M
↓ 41.5%
Shareholders' Equity
$6.2M
↑ 125.1%
Operating Cash Flow
$-16394000.00
↓ 37.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/18/2026 | View on SEC |
| SCHEDULE 13D | 9/17/2026 | View on SEC |
| D | 9/16/2026 | View on SEC |
| 4 | 9/15/2026 | View on SEC |
| 8-K | 9/15/2026 | View on SEC |
| DEFA14A | 9/9/2026 | View on SEC |
| 3 | 9/1/2026 | View on SEC |
| 8-K | 8/24/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| 10-Q | 7/31/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | FBLG |
| Company Name | FibroBiologics, Inc. |
| CIK | 1958777 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 281-671-5150 |